BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 12883193)

  • 1. Relationship between postoperative erythromycin breath test and early morbidity in liver transplant recipients.
    Schmidt LE; Rasmussen A; Kirkegaard P; Dalhoff K
    Transplantation; 2003 Jul; 76(2):358-63. PubMed ID: 12883193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early postoperative erythromycin breath test correlates with hepatic cytochrome P4503A activity in liver transplant recipients.
    Schmidt LE; Olsen AK; Stentoft K; Rasmussen A; Kirkegaard P; Dalhoff K
    Clin Pharmacol Ther; 2001 Nov; 70(5):446-54. PubMed ID: 11719731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of interpatient and intrapatient variation in OG 37-325 dosing requirements by the erythromycin breath test. A prospective study in renal transplant recipients.
    Turgeon DK; Leichtman AB; Blake DS; Schmouder RL; Lown KS; Annesley TM; Watkins PB
    Transplantation; 1994 Jun; 57(12):1736-41. PubMed ID: 8016878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytochrome P450 3A4 activity after surgical stress.
    Haas CE; Kaufman DC; Jones CE; Burstein AH; Reiss W
    Crit Care Med; 2003 May; 31(5):1338-46. PubMed ID: 12771600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of cyclosporine clearance in liver transplant recipients by the use of midazolam as a cytochrome P450 3A probe.
    Villeneuve JP; L'Ecuyer L; De Maeght S; Bannon P
    Clin Pharmacol Ther; 2000 Mar; 67(3):242-8. PubMed ID: 10741627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Importance of cytochrome P-450IIIA activity in determining dosage and blood levels of FK 506 and cyclosporine in liver transplant recipients.
    Cakaloglu Y; Tredger JM; Devlin J; Williams R
    Hepatology; 1994 Aug; 20(2):309-16. PubMed ID: 7519161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term evaluation of cyclosporine and tacrolimus based immunosuppression in pediatric liver transplantation.
    Hasenbein W; Albani J; Englert C; Spehr A; Grabhorn E; Kemper MJ; Burdelski M; Ganschow R
    Pediatr Transplant; 2006 Dec; 10(8):938-42. PubMed ID: 17096762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
    Fukudo M; Yano I; Yoshimura A; Masuda S; Uesugi M; Hosohata K; Katsura T; Ogura Y; Oike F; Takada Y; Uemoto S; Inui K
    Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ACE gene D/D genotype as a risk factor for chronic nephrotoxicity from calcineurin inhibitors in liver transplant recipients.
    Gallon L; Akalin E; Lynch P; Rothberg L; Parker M; Schiano T; Abecassis M; Murphy B
    Transplantation; 2006 Feb; 81(3):463-8. PubMed ID: 16477235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine.
    Stein CM; Kinirons MT; Pincus T; Wilkinson GR; Wood AJ
    Clin Pharmacol Ther; 1996 Jan; 59(1):47-51. PubMed ID: 8549033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
    Fairbanks KD; Eustace JA; Fine D; Thuluvath PJ
    Liver Transpl; 2003 Oct; 9(10):1079-85. PubMed ID: 14526403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
    DuBay D; Smith RJ; Qiu KG; Levy GA; Lilly L; Therapondos G
    Liver Transpl; 2008 May; 14(5):651-9. PubMed ID: 18433069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythromycin breath test.
    Watkins PB
    Clin Pharmacol Ther; 2000 May; 67(5):577-8. PubMed ID: 10824637
    [No Abstract]   [Full Text] [Related]  

  • 15. A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients.
    Shenoy S; Hardinger KL; Crippin J; Korenblat K; Lisker-Melman M; Lowell JA; Chapman W
    Liver Transpl; 2008 Feb; 14(2):173-80. PubMed ID: 18236391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of albumin supplementation on tacrolimus and cyclosporine therapy early after liver transplantation.
    Trull A; Hughes V; Cooper D; Wilkins M; Gimson A; Friend P; Johnston A; Sharples L; Park G
    Liver Transpl; 2002 Mar; 8(3):224-32. PubMed ID: 11910567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
    Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients.
    Barrera-Pulido L; Aguilera-García I; Docobo-Pérez F; Alamo-Martínez JM; Pareja-Ciuró F; Nuñez-Roldán A; Gómez-Bravo MA; Bernardos-Rodríguez A
    Transplant Proc; 2008 Nov; 40(9):2949-51. PubMed ID: 19010156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.
    Watson CJ; Gimson AE; Alexander GJ; Allison ME; Gibbs P; Smith JC; Palmer CR; Bradley JA
    Liver Transpl; 2007 Dec; 13(12):1694-702. PubMed ID: 18044728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impaired erythropoietin production in liver transplant recipients: the role of calcineurin inhibitors.
    Bardet V; Junior AP; Coste J; Lecoq-Lafon C; Chouzenoux S; Bernard D; Soubrane O; Lacombe C; Calmus Y; Conti F
    Liver Transpl; 2006 Nov; 12(11):1649-54. PubMed ID: 17058250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.